^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
ADXS-PSA
i
Other names: ADXS-PSA, ADXS31-142, live attenuated Listeria-based prostate cancer vaccine, Lovaxin P, ADXS PSA, ADXS 31142, ADXS-31142
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Ayala Pharma
Drug class:
KLKB1 inhibitor
Related drugs:
10ms
KEYNOTE-046: ADXS31-142 Alone and in Combination With Pembrolizumab (MK-3475) in Participants With Previously Treated Metastatic Castration-Resistant Prostate Cancer (mCRPC) (clinicaltrials.gov)
P1/2, N=50, Completed, Advaxis, Inc. | Unknown status --> Completed
Trial completion • Combination therapy • Metastases
|
Keytruda (pembrolizumab) • ADXS-PSA
5years
KEYNOTE-046 (Part B): Effects of ADXS-PSA in combination with pembrolizumab on survival in metastatic, castration-resistant prostate cancer patients with or without prior exposure to docetaxel. (ASCO-GU 2020)
Results with ADXS-PSA in combination with pembrolizumab in mCRPC, with or without prior docetaxel, show promising clinical activity to be further assessed in randomized studies. Clinical trial information: NCT02325557. Research Funding: None.
Clinical • Combination therapy
|
KLK3 (Kallikrein-related peptidase 3)
|
Keytruda (pembrolizumab) • docetaxel • ADXS-PSA
5years
KEYNOTE-046 (Part B): Effects of ADXS-PSA in combination with pembrolizumab on survival in metastatic, castration-resistant prostate cancer patients with or without prior exposure to docetaxel. (ASCO-GU 2020)
Results with ADXS-PSA in combination with pembrolizumab in mCRPC, with or without prior docetaxel, show promising clinical activity to be further assessed in randomized studies. Clinical trial information: NCT02325557. Research Funding: None.
Clinical • Combination therapy
|
KLK3 (Kallikrein-related peptidase 3)
|
Keytruda (pembrolizumab) • docetaxel • ADXS-PSA
Share via
